Targets › RBP4
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Feb 2028.
Retinol-binding protein that mediates retinol transport in blood plasma. Delivers retinol from the liver stores to the peripheral tissues (Probable). (UniProt, P02753)
Open in Phaseline: the race on RBP4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City Therapeutics | CITY-RBP4 siRNA targeting RBP4 | RBP4 | Phase 1 | Stargardt Disease 1 | Feb 2028 |
Stargardt Disease 1 (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.